A Randomized, Double-blind, Parallel Group, Multicenter Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid Arthritis (RA)
Phase of Trial: Phase I
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Acronyms RAMO-1
- Sponsors Archigen Biotech
- 09 Aug 2017 Planned End Date changed from 1 Jun 2018 to 1 Oct 2018.
- 09 Aug 2017 Planned primary completion date changed from 1 Dec 2017 to 1 May 2018.
- 13 Jul 2016 New trial record